Anatomic Stage II Breast Cancer AJCC v8 Clinical Trials in West Bloomfield, Michigan

5 studies are recruiting for anatomic stage ii breast cancer ajcc v8 in West Bloomfield, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

   This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan

   Locations

   556 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06058377 on ClinicalTrials.gov

2. Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

   This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer returning (low risk recurrence). Ribociclib may stop the growth…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan

   Locations

   183 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT07391774 on ClinicalTrials.gov

3. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

   This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complete response (pCR) after preoperative (neoadjuvant) chemothera…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan

   Locations

   690 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT06876714 on ClinicalTrials.gov

4. Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

   This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achieved a pathologic complete response after preoperative chemot…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan

   Locations

   846 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT05812807 on ClinicalTrials.gov

5. Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

   This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells f…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan

   Locations

   963 in total

   Run by

   SWOG Cancer Research Network

   See if you can join NCT05929768 on ClinicalTrials.gov